Ranibizumab for Neovascular Age-Related Macular Degeneration
Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimall...
Publications
2 shownRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 9,178
- Institution
- Cleveland Clinic
External Links
Identifiers
- ORCID
- 0000-0001-5126-045X
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.